EP1973871A1 - Derives de diphenyluree - Google Patents

Derives de diphenyluree

Info

Publication number
EP1973871A1
EP1973871A1 EP06829407A EP06829407A EP1973871A1 EP 1973871 A1 EP1973871 A1 EP 1973871A1 EP 06829407 A EP06829407 A EP 06829407A EP 06829407 A EP06829407 A EP 06829407A EP 1973871 A1 EP1973871 A1 EP 1973871A1
Authority
EP
European Patent Office
Prior art keywords
compounds
treatment
pharmaceutical compositions
infections
anaerobic gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06829407A
Other languages
German (de)
English (en)
Inventor
Ralf Loewe
Sergio Lociuro
Stephen Hawser
Laurent Schmitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arpida AG
Original Assignee
Arpida AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arpida AG filed Critical Arpida AG
Priority to EP06829407A priority Critical patent/EP1973871A1/fr
Priority claimed from PCT/EP2006/011795 external-priority patent/WO2007068395A1/fr
Publication of EP1973871A1 publication Critical patent/EP1973871A1/fr
Withdrawn legal-status Critical Current

Links

Definitions

  • the present invention relates to novel 1 ,3-diphenyl ureas which are specifically trifluoromethyl and halogen substituted in the phenyl rings, to pharmaceutical compositions containing them and to their use in the treatment and/or prevention of bacterial infections.
  • novel 1 ,3-diphenyl ureas with a distinct halogen/trifluromethyl substitution pattern are specifically active against bacteria and exhibit virtually no activity against fungi and that these novel 1 ,3-diphenyl ureas are very potent against a broad range of aerobic and anaerobic Gram-positive pathogens including, among others, multi-drug resistant staphylococci, e.g., S. aureus and S. epidermidis, enterococci, e.g., E. faecalis, streptococci, e.g., S. pneumoniae, S. pyogenes and S. viridans.
  • multi-drug resistant staphylococci e.g., S. aureus and S. epidermidis
  • enterococci e.g., E. faecalis
  • streptococci e.g., S. pneumoniae, S. pyogenes and S. viridans.
  • Preferred applications for the compounds of the present invention are those related to the topical/localized treatment of infections in humans and in animals and to the decolonization and/or prevention of colonization of any site which is needed to be rendered sterile from bacteria or in which the bacterial load has to be decreased to prevent spread of bacteria to other sites and to cause infections.
  • Examples of these applications are treatment of skin, mucosal, ocular, dental, gastro-intestinal and upper respiratory-tract infection, decolonization and/or prevention of bacterial colonization of, among others, skin, eyes, nares, mouth, mucosa, gastro-intestinal tract, upper respiratory tract, prosthetic devices and surfaces in general where bacteria can survive and eventually replicate e.g., before surgical practice and/or in general in any instance in which decolonization and/or prevention of spread of bacteria to other sites, which bacteria can infect or colonize, is required.
  • R represents chlorine or bromine
  • X represents oxygen or sulfur; and pharmaceutically acceptable salts thereof.
  • compositions of this invention encompasses salts with a strong base like an alkali or earth alkali base, e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide etc., or e.g. choline etc. Because of their ability to inhibit aerobic and anaerobic Gram-positive bacteria, compounds of this invention can be used for the treatment of human and animal diseases which are typically associated with one or more of such type of pathogens and/or in the decolonization of and/or in the prevention of colonization by one or more of such type of bacteria. This makes compounds of this invention valuable antibacterial agents.
  • a strong base like an alkali or earth alkali base, e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide etc., or e.g. choline etc.
  • the described compounds can be administered by all means known in the art such as, among others, orally, intravenously, topically, rectally, vaginally, sublingually, by inhalation or by any means of local delivery depending on the site were bacteria are localized as colonizers or as infecting agents.
  • Examples of applications are capsules, tablets, orally administered suspensions or solutions, suppositories, injections, eye-drops, ointments, aerosols/nebulizers or topical/localy administered forms.
  • Examples of topical forms and of forms suitable for local delivery can be, among others, gels, creams, ointments, pastes, lotions, solutions, sprays, lozenges, tablets, capsules, sachet, suspension, suppositories, ovules, lacquers, cements, etc.
  • colonisation e.g., skin, mucosa, eye, ear, mouth, nares, parts of the gastro-intestinal tract or of the upper-respiratory tract, prosthetic devices.
  • the described compounds can be also incorporated in the cement and/or in parts of a prosthetic device from which they are released in order to prevent its colonization.
  • Preferred applications are oraly, topicaly as well as eye drops.
  • the dosage used depends upon the type of the specific active ingredient, the use in animal or human, the kind of administration and in case of application in man, the age and the requirements of the patient. Generally, dosages of 0.01 - 50 mg / kg body weight per day either as a single or subdivided in 2 to 4 doses per day are considered. For liquid or semi-solid formulations, e.g. solutions, ointments, gels or creams anvile amount of a formulation with a ratio between the active ingredient and the excipients in a range between 0.01 % to 5 % are considered. These dosage should be administered preferably in 1 to 4 doses per day which are of equal amounts. As usual children should receive lower doses which are adapted to body weight and age.
  • compositions with compounds of formula I can contain inert excipients or also excipients with antibacterial activity.
  • Tablets or granules, for example, could contain a number of binding agents, filling excipients, carrier substances or diluents.
  • compositions outlined above may be administered in enteral, oral form or in topical form e.g. as tablets, dragees, gelatine capsules, emulsions, solutions, creams, ointment or suspensions, in intranasal form like sprays or rectally in form of suppositories.
  • enteral, oral form or in topical form e.g. as tablets, dragees, gelatine capsules, emulsions, solutions, creams, ointment or suspensions, in intranasal form like sprays or rectally in form of suppositories.
  • These compounds may also be administered parenteral, in intramuscular or intraveneous form, e.g. in form of injectable solutions.
  • compositions may contain the compounds of formula I as well as their pharmaceutically acceptable salts in combination with inorganic and/or organic excipients which are usual in the pharmaceutical industry like lactose, maize or derivatives thereof, talcum, stearinic acid or salts of these materials.
  • vegetable oiis waxes, fats, liquid or half-liquid polyols etc. may be used.
  • solutions and syrups e.g. water, polyols, saccharose, glucose etc. are used.
  • injectables are prepared by using e.g. water, polyols, alcohols, glycerin, vegetable oils, lecithin, liposomes etc.
  • Suppositories are prepared by using natural or hydrogenated oils, waxes, fatty acids (fats), liquid or half-liquid polyols etc.
  • compositions may contain in addition preservatives, stabilisation improving substances, viscosity improving or regulating substances, solubility improving sub- stances, sweeteners, dyes, taste improving compounds, salts to change the osmotic pressure, buffer, antioxidants etc.
  • the compounds of formula I may also be used in co-therapy with one or more other therapeutics, for example with other classes of anti-infective agents to increase/ complement their anti-infective spectrum of action, e.g. penicillins and cephalo- sporins; glycopeptides; quinolones; tetracyclines; aminoglycosides; macrolides, sulfonamides etc. or antifungals, antiprotozals etc.
  • other therapeutics e.g. penicillins and cephalo- sporins; glycopeptides; quinolones; tetracyclines; aminoglycosides; macrolides, sulfonamides etc. or antifungals, antiprotozals etc.
  • Compounds of this invention can be also incorporated in cleaning and/or cleansing solutions and/or dressings and/or coatings and/or lacquers and/or cements and/or parts of a prosthetic device for decolonization and/or prevention of bacterial colonization of sites in which bacteria can survive and eventually replicate causing potential risk for infections.
  • Clinical and Laboratory Standards Institute (CLSI; formerly NCCLS): Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard - Seventh Edition (2006). Clinical and Laboratory Standards Institute document M7-A7.
  • Streptococci S. pneumoniae, S. pyogenes, S. viridans
  • CLSI National Committee for Clinical Laboratory Standards
  • MIC Minimum Inhibitory Concentration
  • MIC Minimum Inhibitory Concentration
  • MIC Minimum Inhibitory Concentration
  • MIC Minimum Inhibitory Concentration

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne de nouvelles 1,3-diphénylurées, notamment trifluorométhyle et à substitution d'halogène, et leur utilisation comme principes actifs dans la préparation de compositions pharmaceutiques. L'invention concerne aussi la préparation des composés, les compositions pharmarceutiques contenant un ou plusieurs des composés et, plus précisément, leur utilisation comme anti-infectieux.
EP06829407A 2005-12-13 2006-12-08 Derives de diphenyluree Withdrawn EP1973871A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06829407A EP1973871A1 (fr) 2005-12-13 2006-12-08 Derives de diphenyluree

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2005/013345 2005-12-13
PCT/EP2006/011795 WO2007068395A1 (fr) 2005-12-13 2006-12-08 Derives de diphenyluree
EP06829407A EP1973871A1 (fr) 2005-12-13 2006-12-08 Derives de diphenyluree

Publications (1)

Publication Number Publication Date
EP1973871A1 true EP1973871A1 (fr) 2008-10-01

Family

ID=39719133

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06829407A Withdrawn EP1973871A1 (fr) 2005-12-13 2006-12-08 Derives de diphenyluree

Country Status (1)

Country Link
EP (1) EP1973871A1 (fr)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007068395A1 *

Similar Documents

Publication Publication Date Title
US8900625B2 (en) Antimicrobial compounds and methods of use
JP5372505B2 (ja) 抗菌活性を示すプレウロムチリン誘導体
KR100893426B1 (ko) 항균 활성을 갖는 플레우로무틸린 유도체
WO2010136804A1 (fr) Dérivés de pyrimidine à utiliser en tant qu'antibiotiques
US7696249B2 (en) Diphenyl urea derivatives
CZ196494A3 (en) N,n'-substituted imidocarbonimidediamides derived from hydroxylamines
EP2678307A1 (fr) Utilisation de dérivés de polyamino-isoprényle dans un traitement antibiotique ou antiseptique
JP2018087191A (ja) 環状骨格ペプチドの組合せ
US3300378A (en) Disinfectant and anti-inflammatory composition and method of using same
US8058468B2 (en) Carbamate antibiotics
EP1973871A1 (fr) Derives de diphenyluree
EP1993997A2 (fr) Derives de la diphenyluree
ES2699001T3 (es) Nuevo compuesto antibacteriano de oxazolidinona
EP1435928A1 (fr) Allicine
AU2002334074A1 (en) Allicin
MX2008007478A (es) Derivados de difenilurea
CN110372624A (zh) 一种噁唑烷酮类化合物、其制备方法及应用
Vitnik et al. Improved synthesis and in vitro study of antimicrobial activity of α, β-unsaturated and α-bromo carboxylic acids
JPS62129217A (ja) 医薬用殺菌組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080708

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20090729

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110701